Targets › SURVIVIN
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on SURVIVIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Catherine Bollard | Tumor associated antigen lymphocytes (TAA-T) Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN | WT1, PRAME, SURVIVIN | Phase 1 | Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain Tumor | Nov 2026 |
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.